SCHEMBL3600144

SCHEMBL3600144

c1ccc(-c2cnn(CCN3CCCCC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
ACHE P22303 3/20 0.48
SIGMAR1 Q99720 2/20 0.47
ACP1 P24666 2/20 0.44
SMARCA2 P51531 1/20 0.44
HRH3 Q9Y5N1 3/20 0.43
HRH1 P35367 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3596667 1.00 CYP1A2 (0.56) CYP1A2CYP2D6CYP2C19ACHESIGMAR1
Oxalic Acid SCHEMBL3598170 0.93 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19HRH3HRH1
Oxalic Acid SCHEMBL3600474 0.93 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19HRH3HRH1
Oxalic Acid SCHEMBL3600180 0.93 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19HRH3HRH1
Oxalic Acid SCHEMBL3600469 0.93 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19HRH3HRH1
SCHEMBL3606647 0.91 HRH3 (0.51) CYP1A2CYP2D6CYP2C19ACHEACP1
SCHEMBL467285 0.91 HRH3 (0.51) CYP1A2CYP2D6CYP2C19ACHEACP1
SCHEMBL14760320 0.91 HRH3 (0.54) SIGMAR1ACP1HRH3HRH1KCNH2
SCHEMBL29009117 0.86 LMNA (0.47) CYP1A2CYP2D6ACHESIGMAR1ACP1
Oxalic Acid SCHEMBL3598353 0.85 HRH3 (0.54) CYP2D6HRH3HRH1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097392-B1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS ESTEVE LABOR DR (ES) 2013-03-13 EP claimed
US-8193223-B2 1,2,3-triazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-05 US claimed
US-20100004265-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. 2010-01-07 US claimed
EP-2097392-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-09-09 EP claimed
WO-2008055933-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-05-15 WO claimed
EP-2097392-B1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS ESTEVE LABOR DR (ES) 2013-03-13 EP disclosed
US-8193223-B2 1,2,3-triazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-05 US disclosed
US-20100004265-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. 2010-01-07 US disclosed
EP-2097392-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-09-09 EP disclosed
WO-2008055933-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004265-A1 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS SIGMAR1, OPRK1, OPRD1 CYP1A2 86/4885CYP2D6 256/4885CYP2C19 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.